Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diakine TCE Combination (Autoimmune)
- Development stage
- Preclinical
- Lead developer
- DEKA Biosciences
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Diakine TCE Combination (Autoimmune) is a preclinical-stage therapeutic candidate being developed by DEKA Biosciences for the treatment of autoimmune B cell-mediated diseases. The therapy utilizes a combination of T-cell engager (TCE) molecules designed to recruit and activate T cells to selectively eliminate pathogenic B cells. By facilitating the targeted depletion of autoimmune B cell populations, this combination approach aims to address the underlying drivers of various autoimmune conditions. The candidate is part of DEKA's Diakine platform, which typically focuses on disease-modifying cytokine fusion proteins, though this specific program is characterized as a T-cell engager combination.
- Other names
- Diakine TCE Combination
02
Targets
CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on Diakine TCE Combination (Autoimmune).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diakine TCE Combination (Autoimmune).